Febuxostat-Products-Jinan Xinnuo Pharmaceutical Technology Co., Ltd.

Description

Febuxostat (INN; trade names Adenuric in Europe and New Zealand, Uloric in the US, Goturic in Latin America, Feburic in Japan) is a drug that inhibits xanthine oxidase, thus reducing production of uric acid in the body. It is used in the treatment of chronic gout and hyperuricemia.

Febuxostat was discovered by scientists at the Japanese pharmaceutical company Teijin in 1998. Teijin partnered the drug with TAP Pharmaceuticals in the US and Ipsen in Europe. Ipsen obtained marketing approval for febuxostat from the European Medicines Agency in April 2008, Takeda obtained FDA approval in February 2009, and Teijin obtained approval from the Japanese "Pharmaceuticals and Medical Devices Agency" in 2011.

Basic Info

Chemical Name	2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
Synonyms	2-(3-Cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic Acid;UNII-101V0R1N2E;Febuxostat;Uloric;Adenuric;Febuxostat,This product is unavailable;Tei-6720;TMX 67;
CAS No.	144060-53-7
Molecular Formula	C16H16N2O3S
Molecular Weight	316.37500
PSA	111.45000
LogP	3.72318

Properties

Appearance & Physical State	Crystalline Solid
Density	1.31 g/cm3
Boiling Point	536.6ºC at 760 mmHg
Melting Point	238-239ºC
Flash Point	278.3ºC
Refractive Index	1.605
Vapor Pressure	2.41E-12mmHg at 25°C

Safety Info

HS Code

2934100090

Company Profile

Jinan Xinnuo Pharmaceutical Technology Co., Ltd. is a high-tech enterprise specializing in the production of pharmaceutical intermediates. The company has been engaged in the research, development and production of chemical intermediates for more than 10 years. It integrates research, development, production, import and export trade, strong technical force, advanced testing methods, strong research and development capabilities and superb synthetic technology. It is an incubator of Jinan Pharmaceutical Valley. Committed to gout, nutrition, anti-cancer, anti-depression, anti-age dementia and drug synthesis in the cardiovascular and cerebrovascular fields. The products are mainly exported, and the products are exported to more than 40 countries and regions such as Southeast Asia, South America and Eastern Europe.

The company has a complete quality assurance system and strong scientific research and innovation strength. Every year, new market-oriented and high-tech synthetic drugs are launched. We are willing to provide you with quality products and competitive prices. Efficient service.